Abstract. In the present study, we investigated the expression of ubiquitin-like with PHD and ring finger domains 2 (UHRF2) in colon cancer and adjacent normal tissues and estimated the clinicopathological significance and predictive value of UHRF2 expression in colon cancer. Using quantitative real-time PCR, tissue microarray (TMA), western blot analysis and immunohistochemical staining, we evaluated UHRF2 mRNA and protein levels in tumor tissues and paired adjacent normal epithelium. We found that UHRF2 was upregulated at both the transcriptional and translational levels in tumor tissues. Immunohistochemical detection of UHRF2 on a TMA containing 203 paired specimens showed that increased cytoplasmic UHRF2 was significantly associated with clinical stage, depth of invasion, nodal involvement, tumor histologic grade and the presence of metastasis. Patients with UHRF2-positive tumors had a much lower diseasefree survival [hazard ratio (HR) 9.511, P<0.001] and overall survival (HR 9.820, P<0.001). Univariate and multivariate analyses were performed to determine the correlation between these parameters and the clinical and pathological variables of the study population verifying that UHRF2 immunoreactivity emerged as an independent prognostic factor in the multivariate analysis. UHRF2 may contribute to the progression of colon carcinogenesis and function as a novel prognostic indicator after curative operation.
Introduction
Colon cancer is one of the most common malignancies in the world and results from an accumulation of genetic and epigenetic aberrations (1) . It is the second leading cause of cancer mortality in the United States with ~52,000 deaths and 143,000 cases expected in 2012 (2) and ranks the third leading cause of cancer mortality worldwide (3) . In addition, changes in lifestyle and nutrition have led to the rise in colon cancer incidence in China and other economically transitioning countries over the past few decades (4) . In spite of advances in screening and prevention, early detection, adjuvant therapy and treatment of metastatic disease, colon cancer remains the major cause of cancer morbidity and mortality. Evidence has been provided by molecular investigations that multiple alterations in genes of the striking signaling pathway, including adenomatous polyposis coli protein (APC), β-catenin and c-myc, are involved in colonic carcinogenesis (5, 6) . Despite existing intensive study, the molecular mechanisms underlying the development and progression of colon cancer remain poorly understood. It is of great clinical importance to further investigate the molecular mechanisms of this cancer and to find valuable early diagnostic markers with high specificity and sensitivity as well as novel therapeutic targets.
The ubiquitin proteasome system (UPS) regulates the ubiquitination, and thus the degradation and turnover, of many proteins crucial to cellular regulation and function (7) . Aberrancies within the UPS pathway can result in a malignant cellular phenotype which can lead to several types of human malignant cancer (8, 9) . Fundamental to the specificity of this system are ubiquitin-protein ligases (E3s) (10) . Ubiquitin-like with PHD and ring finger domains 2 (UHRF2), a member of the UHRF [ubiquitin PHD really interesting new gene (RING) finger] family, is a nuclear E3 ubiquitin ligase mapped to 9p23-24.1 (11, 12) .
UHRF2 comprises diverse domains including the ubiquitin-like (UBL) domain, tandem Tudor domain (TTD), plant homeo domain (PHD) finger domain, SET and RING associated (SRA) domain and RING finger domain (11) (12) (13) . Due to its multiple domains, UHRF2 has such a complex function that it is involved in cell cycle network, the epigenetic system and the UPS. On account of its three different network modules, UHRF2 plays a contradictory role in tumorigenesis. Using a cancer outlier profile analysis identified that DNA copy number loss of the UHRF2 gene in a variety of malignancies related to the brain (14) . On the contrary, UHRF2 has been proven to play a role as an oncogene in breast cancer cells (15 However, the clinicopathological significance and mechanism of UHRF2 involvement in the aggression of colon cancer is not completely understood. The present study sought to assess the hypothesis that UHRF2 expression is dysregulated in colon cancer at both the mRNA and protein levels and its predictive value in colon cancer. Immunohistochemistry was used to explore the expression of UHRF2 both in primary colon cancer specimens and paired adjacent normal mucosa tissue and investigated whether UHRF2 may be used as an independent biomarker to predict metastasis and prognosis in patients with colon cancer. No patients had received therapy prior to surgery. There were 86 men and 117 women with a mean age of 65±15 years (range, 22-95 years). Formalin-fixed, paraffin-embedded samples for immunohistochemistry were obtained from the 203 colon carcinoma tissues and paired normal mucosal tissue taken from a segment of the resected specimens that was the farthest from the tumor (>10 cm). All tissues were histologically confirmed to be adenocarcinoma of the colon. Patient follow-up was carried out according to the National Comprehensive Cancer Network Practice Guidelines in colon cancer (Engstrom PF.2005; 3:468-91). Disease-free survival (DFS) and overall survival (OS) rates were defined as the interval from the initial surgery to clinically or radiologically proven recurrence/metastasis and death, respectively. The final follow-up was on June 29, 2008 with a median patient follow-up time for survivors of 61 months (range, 9-89 months). Detailed patient demographic information is shown in Table I . Vascular invasion was defined as vessel wall occlusion or destruction, accompanied by a surrounding fibroinflammatory reaction (16) .
Materials and methods

Patients
RNA extraction, reverse transcription PCR and quantitative real-time PCR.
Total RNA in 40 paired, frozen primary colon cancer tissues, and adjacent normal mucosa were extracted according to the manufacturer's instructions (Qiagen, Hilden, Germany). One microgram of total RNA from each sample was subjected to first-strand complementary DNA synthesis using an A3500 RT-PCR System ® according to the recommendations of the manufacturer (Promega Corporation, Madison, WI, USA). To confirm UHRF2 gene expression in colon tumors, relative UHRF2 mRNA levels were assessed by quantitative real-time PCR (qPCR) using Mastercycler ep realplex ® (Eppendorf, Hamburg, Germany) with an IQTM SYBR-Green Supermix kit (Bio-Rad, Berkeley, CA, USA) according to the manufacturer's instructions and using the following thermal cycling conditions: initial denaturation (10 min at 95˚C) followed by 40 cycles of denaturation (10 sec at 95˚C), annealing (15 sec at 58˚C) and elongation (1 min at 72˚C). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The primers for qPCR were: UHRF2 sense, 5'-TTCTTGCTCCTGTCGTGTATGT-3' and antisense, 5'-CTTGAGTCTTTCACCAGCCTTT-3'; GAPDH sense, 5'-GTCCACCACCCTGTTGCTGTA-3' and antisense, 5'-CTTCAACAGCGACACCCACTC-3'. Each reaction was repeated at least three times, and then the mean UHRF2 mRNA level for each tumor was compared with the level of its matched non-tumorous tissue. The fold-change (2 -ΔΔCt ) (17) in UHRF2 expression in each paired sample was calculated using the formulas: UHRF2ΔCt = (Avg.UHRF2_Ct -Avg.GAPDH_Ct), UHRF2ΔΔCt = (UHRF2ΔCt_tumor -UHRF2ΔCt_non-tumor).
Western blot analysis. Total proteins were extracted from 8 paired frozen colon tumor and adjacent normal tissues using radioimmunoprecipitation assay (RIPA) lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) with a protease inhibitor cocktail (0.89 µg/µl; Sigma-Aldrich) and phenylmethanesulfonyl fluoride (17.4 µg/µl) and quantified using a BCA protein assay kit according to the manufacturer's instructions (Beyotime Biotechnology Co., Jiangsu, China). Equivalent amounts of protein were separated by electrophoresis on a 9.0% sodium dodecyl sulphatepolyacrylamide gels and transferred onto polyvinylidene difluoride (PVDF) membranes, which were blocked with 5% non-fat dry milk in 0.05% PBS-T for 1 h at room temperature, followed by incubation with the rabbit anti-UHRF2 polyclonal antibody (1:500) or anti-β-actin monoclonal antibody (1:2,000) (both from Abcam, Cambridge, UK) overnight at 4˚C. After washing with TBST buffer, the membranes were incubated with a goat-anti-rabbit IgG HRP-conjugated secondary antibody (1:5,000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) for 2 h. The membranes were washed, and bound antibodies were detected by enhanced chemiluminescence (Millipore) according to the manufacturer's instructions and were exposed to X-ray film. The abundance of each protein was determined and normalized against β-actin expression.
Tissue microarray (TMA) construction and immunohistochemistry. TMA construction was undertaken as previously reported (18) . Briefly, paraffin-embedded TMA sections were dewaxed and rehydrated before antigen retrieval was carried out. Immunohistochemistry was performed to further evaluate the histological expression of UHRF2. UHRF2 and Ki-67 expression were detected on the TMAs following preheated (95-98˚C) citrate buffer (pH 6.0) for 10 min aimed at antigen retrieval. Immunolabeling was carried out using a primary antibody against UHRF2 (1:50; Abcam) and the proliferation index Ki-67 (1:50; Dako Cytomation, Copenhagen, Denmark). Sections were incubated overnight at 4˚C and then incubated with the secondary antibody (EnVision System, Dako) for 1 h at room temperature. After rinsing three times in PBS for 10 min each, the sections were incubated with 3,3-diaminobenzidine tetrahydrochloride (DAB) liquid for 1 min, counterstained with Mayer hematoxylin, dehydrated and then mounted. The negative control was prepared with normal tissue and without anti-UHRF2 antibody incubation.
Evaluation of immunohistochemical staining. Immunoreactivity was evaluated independently by three researchers who were blinded to patient outcomes (double-blinded) on the basis of the intensity and extent of staining (19) . The staining intensity for UHRF2 was graded as 0 (no staining), 1 (mild staining), 2 (moderate staining) and 3 (intense staining). The staining extent was scored using the scale as follows: 0 (no staining of cells), 1 (<10% of tissue stained positive), 2 (10-50% stained positive), 3 (>50% stained positive). The final staining score was defined as the sum of the intensity and extent scores. The specimens were divided into three groups according to their overall scores as follows: 0-2, expression; 3-4, weak expression; 5-6, strong expression. The Ki-67 proliferation index was on the basis of the percentage of cells with positive nuclear staining and was divided into two groups selecting 10% positively staining nuclei as the cutoff point: negative (≤10% of cells with positive nuclei) and positive (>10% of cells with positive nuclei) (20) . In cases of discrepant assessments, the sections were re-investigated by both pathologists under a multi-head microscope until consensus was achieved.
Statistical analyses. All statistical analyses were performed using the SPSS 16.0 statistics software package (SPSS Inc., Chicago, IL, USA). Paired t-tests were carried out to indicate the expression (ΔCT) of UHRF2 in normal and adjacent cancer tissues. The χ 2 test or Fisher's exact test, where appropriate, for proportionality was used to analyze the relationship between the expression of UHRF2, the Ki-67 proliferation index and the clinicopathological variables. The Kaplan-Meier method was applied to calculate the survival rates and the differences between the survival curves were examined by the log-rank test. Univariate Cox proportional hazards regressions were used to estimate the individual hazard ratio (HR) for the DFS and OS.
The significant variables in the univariate analyses (P<0.05) were then put into the multivariate analysis. A P-value of <0.05 was considered to indicate a statistically significant difference.
Results
Upregulation of UHRF2 expression in primary colon cancer as compared with adjacent normal mucosa. UHRF2 gene expression was confirmed by real-time PCR analysis of primary colon cancer and adjacent normal mucosa from 40 patients with colon cancer with GAPDH as the internal reference. Of the 40 paired cases, 28 (68%) colon cancer tissues showed at least a two-fold increase in UHRF2 mRNA level compared with that of the adjacent non-cancerous mucosa (Fig. 1A) . In patients with colon cancer, the expression (ΔCt) of UHRF2 was 3.51±1.072 in tumor tissue and . This difference in UHRF2 mRNA expression was significant (P<0.001; Fig. 1 ). This suggests that UHRF2 mRNA level was upregulated in cancerous tissues as compared with adjacent normal mucosa. Subsequent western blotting confirmed that UHRF2 protein levels were significantly upregulated in cancerous tissues as compared with adjacent normal mucosa (Fig. 1C) .
Association of UHRF2 TMA immunohistochemical staining with patient clinicopathological parameters. UHRF2 was observed mainly in the cytoplasm of colonic epithelial tumor cells, with nuclear staining only rarely observed by immunohistochemistry (Fig. 2) . As shown in Table I 
Survival analysis and prognostic significance of UHRF2 expression.
To assess the possible association between tumor UHRF2 expression and patient survival, Kaplan-Meier curves with a log-rank test for OS and DFS were undertaken (Fig. 3) . The 5-year OS rate of the 203 patients who underwent curative surgery with primary colon cancer was 68%, with 65 deaths occurring during the follow-up. However, the 5-year DFS rate was 62%, with 74 events occurring. Fifty-four patients (27%) developed distant metastases and 20 patients (9%) were diagnosed with local tumor recurrence. There was a considerable difference in the proportion of samples with metastasis or local recurrence from primary colon cancer between the UHRF2-positive and UHRF2-negative groups. tumor UHRF2 expression had a better 5-year DFS and OS rate than did the group with positive-UHRF2 expression (DFS, 88.4% negative vs. 30% positive; OS, 91.4 vs. 29.5%; P<0.001, respectively). Kaplan-Meier curves showed that the rate of recurrence was significantly elevated with positive-UHRF2 expression (Fig. 3) . The estimated mean OS was significantly different between patients with UHRF2-positive and UHRF2-negative tumors (71.5±2.2 and 58.6±5.0 months, respectively; P<0.001). The estimated mean DFS time was 66.2±2.4 and 54.2±5.9 months for subjects with UHRF2-positive and UHRF2-negative tumors (P<0.001). The DFS and OS rates were significantly decreased with increasing UHRF2 expression (Fig. 3) .
UHRF2 expression ------------------------------------------------------------------------------------------------------------------------
In univariate analysis, patients whose localized colon tumors were UHRF2-positive had a significantly lower 5-year DFS than those with UHRF2-negative tumors [HR 9.511 (95% CI, 4.496-20.118)] ( Fig. 3 ; Table III ). The 5-year OS was also significantly lower in patients with UHRF2-positive tumors than in those with UHRF2-negative tumors [HR 9.820 (95% CI, 4.405-21.891)] (Fig. 3 ; Table IV ). In addition, pT stage (P<0.001), pN stage (P<0.001), AJCC stage (P<0.001), vascular invasion, Ki-67 expression and level of tumor differentiation (P<0.001) were associated with OS and DFS. To further define increased UHRF2 expression as an independent factor influencing tumor recurrence, multivariate analysis was performed using the Cox proportional hazards model for all of the significant variables in the univariate analysis (Tables III and IV) ; this demonstrated that positive tumor UHRF2 expression remained a significant independent prognostic factor for increased disease recurrence and decreased survival.
Discussion
The present study shows for the first time that overexpression of UHRF2 was significantly associated with cancer progression and metastasis independent of pathological Tumor-Node-Metastasis staging. The data support UHRF2 as a novel prognostic indicator of colon cancer outcomes; individuals with UHRF2-strong tumors have poorer OS and DFS as compared to those with UHRF2-negative tumors. Correlations of UHRF2 expression with advancing tumor stages suggest that UHRF2 may contribute to the progression of colon carcinogenesis.
In the fresh colon tissues examined in the present study, real-time PCR, immunostaining and western blotting showed that the elevated expression of UHRF2 occurred both at the transcriptional and post-transcriptional levels. In addition, we found that elevated expression of UHRF2 correlated with several clinicopathological factors including AJCC stage Table III . Cox proportional hazards model univariate and multivariate analyses of individual parameters for correlations with disease-free survival (DFS).
Univariate analysis
Multivariate analysis (P<0.001), T classification (P<0.001), nodal involvement (P<0.001), extent of differentiation (P<0.001) and the presence of distant metastasis (P=0.018).
The UHRF family, including UHRF2 and UHRF1, is considered to be involved in carcinogenesis (11) . UHRF2 is a multidomain protein with 802 amino acid residues that shows high structural similarity to its close homolog UHRF1, a putative oncogenic factor, suggested to be an important biomarker to discriminant several types of cancer (21-23). However, in sharp contrast to UHRF1, the UHRF2 gene is frequently Table IV . Cox proportional hazards model univariate and multivariate analyses of individual parameters for correlations with overall survival (OS).
Multivariate analysis discrepant in tumorigenesis. In the present study, UHRF2 acted as an oncogene in the development and progression of colon cancer, which is in accordance with the role UHRF2 plays in breast cancer. However, other reports have elucidated its role of tumor suppression in malignant glioma (24) . This apparent contradiction arises since UHRF2 is a multiple functional protein that is involved in the coordination of three different network modules as previously demonstrated. It is common knowledge that cancer results from an accumulation of genetic and epigenetic aberrations (1) . Thus, we speculate that UHRF2 may have an oncogenic role in colon cancer by mediating tumor suppressor gene inactivation via both DNA methylation and histone modification pathway development and may promote tumor progression through ubiquitin-mediated degradation of the suppressor such as P53 in colon cancer. It is known that inhibiting the proteasome pathways is a notable strategy for anticancer drug development (25) and UHRF2 is a ubiquitin E3 ligase. Targeting UHRF2 would selectively stabilize a specific cellular protein regulated by it, thus avoiding unwanted effects on other cellular proteins. In brief, UHRF2 is a potential novel therapeutic target in colon cancer. In recent years, our understanding of the metastatic process has significantly evolved. However, the mechanisms involved in colon cancer metastasis are not fully understood as metastasis is a multistep process and requires altered expression of a spectrum of genes (26) . In the present study, we examined the expression of UHRF2 in 95 samples of primary colon cancer with metastasis and 108 samples of primary colon cancer without metastasis. There is a significant difference between them (P<0.001). The expression of UHRF2 was upregulated in the specimens with metastasis compared with those without metastasis (54.7 vs. 21.3%). Finally, our results provide the first evidence that the expression of UHRF2 may be a potential molecular marker. UHRF2 expression was associated with an increased risk of metastasis/local recurrence and was strongly linked to poor survival outcomes, with hazard ratios of 9.511 for DFS and 9.820 for OS in the univariate analysis. In multivariate analysis, UHRF2 expression appeared to be an independent prognostic factor for OS and DFS in colon cancer.
The present study found that increased UHRF2 expression was observed in colon cancer tissue and was associated with multiple clinicopathological factors as well as patient OS and DFS. Further studies are necessary to evaluate the mechanism by which UHRF2 is upregulated in colon cancer, the role of UHRF2 in colon cancer progression as well as its value in the prognosis of this disease.
